Fig. 5: Cross-validation of random forest predicted gene signature in an independent cohort of critical COVID.

a Number of CD14 monocytes, CD16 monocytes, and cDC2 cells sequenced by outcome in this study and that by Liu et al.¹⁹. b Ranked feature importance score from random forest classifier model with key genes annotated in CD14 monocytes in the critically ill cohort in Liu et al.¹⁹. z-score for CEBPD, MAFB, IFITM3, and LGALS1 in CD14 monocytes from Liu et al.¹⁹ c By disease severity pooled at day 0 and d by survival outcome at day 0 (healthy controls, n = 14, and critically ill patients, n = 25; 21 alive and 4 deceased). 13,464 Control, 1297 Moderate day 0, 2798 Severe day 0, and 20,775 Critical day 0 CD14 Monocytes were examined. Ordinary one-way ANOVA statistical tests were used for each comparison. ns denotes not significant and **** denotes p < 0.0001.